$NKTR

Rezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.

Nektar Therapeutics (NKTR) stock is in focus after positive Phase 2b data for rezpegaldesleukin in The Lancet. The stock is up 67% YTD but trades 50% below the average analyst target of $144.40. NKTR has a robust cash position and faces risks like ongoing losses and reliance on trial outcomes.

Nektar Therapeutics (NKTR) granted 25,200 stock options and 5,000 RSUs to new employees under its 2025 Inducement Plan. Options have an exercise price of $74.53, vest over 4 years. Nektar focuses on autoimmune and inflammatory disease treatments, with lead candidate rezpegaldesleukin in clinical trials.

Nektar Therapeutics (NKTR) reported Q2 earnings, highlighting a $1.02B cash balance and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The company expects top-line data in mid-2028 and a potential Biologics License Application submission in 2029. NKTR's operating loss widened to $42.3M, with R&D spending expected to increase. The company raised $373.8M in April 2026 to fund operations.

Nektar Therapeutics reported Q2 2026 earnings with noncash royalty revenue of $10.1M, a net loss of $40.6M, and cash/investments of $1.02B. The company initiated Phase 3 trials for rezpegaldesleukin and updated full-year guidance, including revenue of $40M-$45M and end-of-year cash of $815M-$840M. Management expects a cash runway into Q3 2028, supported by a recent public offering.

U.S. retail sales fell 0.6% in July, per the Department of Commerce, versus a Zacks breakeven; June was 0.2%. Ex-auto retail sales declined 0.3%. Earnings: Applied Materials (AMAT) adjusted EPS $3.50 vs $3.38 est, revenue $9.12B vs +1.31% beat; Nektar (NKTR) adjusted loss $1.23 vs -$2.06 est, revenue $10.13M miss; StoneCo (STNE) EPS $0.47 vs $0.46 est, revenue $709.88M miss.

U.S. stock futures were mixed as the S&P 500 headed for a winning week after a new all-time high. Retail sales fell 0.6% in July, though were up 5% year over year, per the Commerce Department. Earnings: AMAT adjusted EPS $3.50 (vs $3.38 est) on $9.12B revenue; NKTR adjusted loss $1.23 (vs $2.06 est) on $10.13M revenue; STNE adjusted EPS $0.47 (vs $0.46 est) on $709.9M revenue.

Nektar Therapeutics (Nasdaq: NKTR) reported Q2 2026 results. Cash and marketable securities were $1,023.4M at June 30, 2026. Revenue was $10.1M vs $11.2M a year earlier. Operating costs were $52.5M and net loss was $40.6M ($1.23/share). Company said Phase 3 ZENITH AD trials began and cash runway extends into Q3 2028.

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nektar Therapeutics Announces Second Quarter 2026 Financial Results SAN FRANCISCO, Aug 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial r

A roundup of Wall Street analyst actions on Wednesday includes Stifel upgrading DigitalOcean to buy, Truist upgrading CoreWeave to buy, and multiple initiations: Philip Morris at buy, Affirm at outperform, Nebius at outperform ($250 target), Digital Turbine at buy ($15), CoreWeave at outperform ($100), and DigitalOcean at outperform ($165). Wells Fargo raised Sandisk to equal weight with a $1,620 target; JPMorgan reiterated Shopify overweight. Other calls cover Disney, Fluence Energy, Vornado, a